Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma

References

• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der L H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?. J Clin Oncol 2000; 18: 332–339
   PubMed Web of Science ®Google Scholar
• Shipp M A, Abeloff M D, Antman K H, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429
   PubMed Web of Science ®Google Scholar
• Stiff P J, Dahlberg S, Forman S J, McCall A R, Horning S J, Nademanee A P, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens—a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48–55
   PubMed Web of Science ®Google Scholar
• Phillips G L, Fay J W, Herzig R H, Lazarus H M, Wolff S N, Lin H S, et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75: 831–838
   PubMed Web of Science ®Google Scholar
• Petersen F B, Appelbaum F R, Hill R, Fisher L D, Bigelow C L, Sanders J E, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638–647
   PubMed Web of Science ®Google Scholar
• Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Lennert K, Feller A. Histopathology of non-Hodgkin's lymphomas. Springer-Verlag, HeidelbergGermany 1992; 53–163
   Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M G, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580–586
   PubMed Web of Science ®Google Scholar
• Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Farber L, et al. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998; 22: 625–630
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 457–481
   Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go?. Semin Oncol 2000; 27: 540–559
   PubMed Web of Science ®Google Scholar
• Armitage J O, Cheson B D. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 1335–1347
   PubMed Web of Science ®Google Scholar
• Villela L, Lopez-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001; 91: 1557–1562
   PubMed Web of Science ®Google Scholar
• Salar A, Martino R, Altes A, Sureda A, Brunet S, Sierra J. High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma. Haematologica 2000; 85: 217–219
   PubMed Web of Science ®Google Scholar
• Haq R, Sawka C A, Franssen E, Berinstein N L. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35: 527–536
   PubMed Web of Science ®Google Scholar
• Reiser M, Josting A, Dias W P, Draube A, Scheid C, Tesch H, et al. Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 33: 305–312
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Hagemeister F B, McLaughlin P, Velasquez W S, Riggs S, Fuller L, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407–412
   PubMed Web of Science ®Google Scholar
• Mahendra P, Johnson D, Hood I M, Scott M A, Barker P, Bass G, et al. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients. Bone Marrow Transplant 1996; 17: 973–978
   PubMed Web of Science ®Google Scholar
• Gulati S, Yahalom J, Acaba L, Reich L, Motzer R, Crown J, et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936–941
   PubMed Web of Science ®Google Scholar
• Rapoport A P, Lifton R, Constine L S, Duerst R E, Abboud C N, Liesveld J L, et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997; 19: 883–890
   PubMed Web of Science ®Google Scholar
• Dreger P, Marquardt P, Haferlach T, Jacobs S, Mulverstedt T, Eckstein V, et al. Effective mobilisation of peripheral blood progenitor cells with ‘Dexa-BEAM’ and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950–957
   PubMed Web of Science ®Google Scholar
• Kroger N, Zeller W, Fehse N, Hassan H T, Kruger W, Gutensohn K, et al. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998; 102: 1101–1106
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Hedrick E E, Donnelly G B, Hunte S, Priovolos A C, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399–2404
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Wilson W H, Bryant G, Bates S, Fojo A, Wittes R E, Steinberg S M, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Soussain C, Souleau B, Gabarre J, Zouabi H, Sutton L, Boccaccio C, et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 1999; 33: 543–550
   PubMed Web of Science ®Google Scholar
• Girouard C, Dufresne J, Imrie K, Stewart A K, Brandwein J, Prince H M, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997; 8: 675–680
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma—the Nordic Lymphoma Group experience. Eur J Haematol 2004; 73: 179–182
   PubMed Web of Science ®Google Scholar
• Josting A, Sieniawski M, Glossmann J P, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16: 1359–1365
   PubMed Web of Science ®Google Scholar
• Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 627–636
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Hosing C, Okoroji G J, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247
   PubMed Web of Science ®Google Scholar
• Musolino A, Perrone M A, Michiara M, Delnevo D, Franciosi V, Di Blasio B, et al. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 2005; 103: 2109–2117
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16: 786–792
   PubMed Web of Science ®Google Scholar